Table 1.
General Baseline Characteristics Of Subjects Who Received Either Saffron Or Placebo
| Variables | Saffron Groupa | Placebo Groupb | p Valuec | |
|---|---|---|---|---|
| Age (years) | 55.2±7.3 | 53±10.6 | 0.61 | |
| Sex | Male n(%) | 20 (50) | 1638 | 0.51 |
| Female n(%) | 20 (50) | 24 (60) | ||
| Height (cm) | 162±9.9 | 163.7±8.3 | 0.41 | |
| Weight (kg) | 75.3±12.8 | 80.3±12.8 | 0.08 | |
| BMI (kg/m2) | 29.3±4.9 | 30.5±4.7 | 0.25 | |
| WC (cm) | 106±9.5 | 107.8±12.9 | 0.75 | |
| Duration of type 2 diabetes (year) | 7.8±5.4 | 6.6±6.1 | 0.13 | |
| Types of hypoglycemic drugs | Metformin n (%) | 4 (10) | 6 (15) | 0.454 |
| Metformin+glibenclamide n(%) | 8 (20) | 13 (32.5) | ||
| Metformin+glibenclamide+zeptin n (%) | 10 (25) | 8 (20) | ||
| Other drugs n (%) | 18 (45) | 13 (32.5) | ||
Notes: All quantitative values are means±SDs. All qualitative values are expressed as numbers and percentages (%). aReceived 100 mg saffron per day during the study. bReceived 100 mg placebo per day during the study. cObtained from independent-samples t-test for quantitative values and Chi-square for qualitative values.
Abbreviations: BMI, body mass index; WC, waist circumference.